Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Trial details
- Registry ID
- NCT03604198
- Phase
- Phase 2
The FDA approved relacorilant (CORT125134) on 25 Mar 2026.
Drug identity checked against registry records
Also recorded as CORT125134
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeNCT03604198 | Corcept Therapeutics | Phase 2 | Active not recruiting | 2026-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-03-25Day | relacorilant | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA220641", "applicant_as_listed_by_fda": "CORCEPT THERAP", "brand_names": ["LIFYORLI (COPACKAGED)"], "active_ingredients": ["RELACORILANT"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20260325", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |